“…[24][25][26][27][28] The latter approach is particularly attractive as MA is a bioprivileged molecule with substantial potential for diversification to commodity and specialty chemicals, as well as novel molecules for enhanced end-use properties (Scheme 1). [29][30][31] Previous work has already demonstrated the conversion of MA to an array of aliphatic commodity monomers including adipic acid and hexamethylenediamine, 24,25,[32][33][34][35][36] cyclic monomers such as εcaprolactam, 37,38 TPA and CHDA, 5,19,39,40 and novel monounsaturated compounds such as 3-hexenedioic acid and 1,4cyclohex-1/2-enedicarboxylic acid (CH1DA, CH2DA). 19,[41][42][43][44] Although the downstream production of cyclic molecules has experienced some significant advances, 39,45 the initial isomerization of biologically-produced cis,cis-muconic acid (ccMA) to Diels-Alder active trans,trans-muconic acid (ttMA) remains a major bottleneck.…”